VP Corporate Finance

Vice President, Corporate Finance

Immix Biopharma, Inc (NASDAQ:IMMX)

Los Angeles, CA / Hybrid

Our 3 Core Values

• Intelligence
• Integrity
• Initiative

What You'll Do

• Financial Reporting and Compliance: Lead the financial reporting process, ensuring accuracy of SEC filings and compliance with regulatory standards
• Oversee budgeting, forecasting, and financial analysis to support decision-making processes
• Accounting Oversight: Manage and oversee the accounting functions, ensuring proper maintenance of all accounting systems and implementing best practices
• Prepare Audit Committee and Board of Directors Financial Reports
• Lead financial audits and manage relationships with external auditors
• Risk Management: Develop and implement risk management policies and procedures
• Monitor and mitigate financial risks and exposures

Skills and Experience We Look For

• 5-10+ years of Finance, Accounting, or related field
• CPA preferred
• Primary responsibility for U.S. Nasdaq/NYSE Listed Company Regulatory Filings in prior roles, preferably in biotechnology or related field
• Bachelor's degree in Finance, Accounting, or related field
• Exceptional project management skills, organizational and problem-solving skills
• Eager to learn with a collaborative, team-oriented mindset.
• Excellent written and verbal communication skills with an ability to express complex ideas to study personnel at research and clinical institutions.

Rewards at Immix

Our people are our greatest asset, and supporting their well-being is an essential part of delivering on our mission and impacting the lives of patients. Putting this belief into practice means offering strong compensation and benefits. Compensation will be commensurate with experience. Our compensation package also includes an annual bonus based on company goals and an equity grant. Our benefits package includes: coverage for medical, dental and vision for team members and dependents and 401k.

About Immix Biopharma, Inc.

Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease. Our lead cell therapy is FDA IND cleared next generation CAR-T NXC-201, currently being evaluated in our ongoing Phase 1b/2a NEXICART-1 (NCT04720313) clinical trial. NXC-201 has the potential to be the world’s first “Single-Day CRS” CAR-T (CRS median onset day 1, median duration 1 day), enabling the potential for a faster return home for patients and supporting ongoing expansion into autoimmune indications. NXC-201 has been awarded Orphan Drug Designation (ODD) by the FDA in both AL Amyloidosis and multiple myeloma, and ODD by the European Commission (EMA) in AL Amyloidosis. Learn more at www.immixbio.com and www.BeProactiveInAL.com.